Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

291
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
291
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

456
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
456
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

665
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
665
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

523
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
523

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A microphysiological spheroid system for modeling glioblastoma structure and therapy response.

Biochemical and biophysical research communications·2026
Same author

Evaluation of Xpert MTB/XDR and Deeplex Myc-TB for the Rapid Detection of Drug Resistance in <i>Mycobacterium tuberculosis</i>.

International journal of microbiology·2026
Same author

Innate Immune Receptor NLRX1: Potential Modulator of Glioblastoma Pathophysiology.

Journal of cellular physiology·2026
Same author

The role of NLRP3 and NLRP12 inflammasomes in glioblastoma.

Genes and immunity·2024
Same author

Characterisation of <i>Neisseria gonorrhoeae</i> strain differences in patients with multisite infection.

Sexually transmitted infections·2024
Same author

Ultrashort segment adult Hirschsprung disease: A case report of periodic abdominal distension and constipation spanning for more than 20 years.

Radiology case reports·2024

Related Experiment Video

Updated: Sep 17, 2025

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

33.5K

Innate immune activation and neuroinflammatory pathways in Epilepsy.

Priya Solanki1, Sushmita Jha1

  • 1Department of Bioscience and Bioengineering, Indian Institute of Technology, Jodhpur, Rajasthan, India.

Cytokine & Growth Factor Reviews
|July 3, 2025
PubMed
Summary

Epilepsy affects millions globally, with many cases resistant to anti-epileptic drugs (AEDs). This review explores neuroinflammation, focusing on glia and signaling pathways, to understand epilepsy development and progression.

Keywords:
Anti-epileptic drugsDrug-resistant epilepsyEpilepsyGliaNeuroinflammationPattern-recognition receptors

More Related Videos

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.6K
Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

2.7K

Related Experiment Videos

Last Updated: Sep 17, 2025

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

33.5K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.6K
Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

2.7K

Area of Science:

  • Neuroscience
  • Immunology
  • Neurology

Background:

  • Epilepsy is a prevalent neurological disorder affecting over 50 million worldwide.
  • Approximately 30% of epilepsy patients exhibit drug-refractory epilepsy, facing cognitive decline and persistent seizures.
  • Neuroinflammation is implicated in epilepsy, but the precise mechanisms remain unclear.

Purpose of the Study:

  • To review the cells and molecules involved in neuroinflammation and epilepsy.
  • To elucidate the role of glia (astrocytes and microglia) in initiating neuroinflammation.
  • To discuss downstream signaling pathways and potential therapeutic targets for epilepsy.

Main Methods:

  • Literature review of neuroinflammatory pathways in epilepsy.
  • Analysis of glial cell function (astrocytes, microglia) in sensing and initiating neuroinflammation.
  • Examination of pattern recognition receptors (TLRs, NLRs) and cytokine/chemokine signaling.

Main Results:

  • Glia, including astrocytes and microglia, play a key role in sensing and initiating neuroinflammation.
  • Pattern recognition receptors and downstream signaling pathways involving cytokines and chemokines are critical.
  • Understanding these pathways offers potential therapeutic intervention points.

Conclusions:

  • Dysregulated neuroinflammation is a critical factor in epilepsy development and progression.
  • Targeting glial-mediated inflammatory pathways presents a promising therapeutic strategy for drug-refractory epilepsy.
  • Further research into neuroinflammatory mechanisms is essential for advancing epilepsy treatment.